

**Supplementary material****Myocardial Extracellular Volume Is not Associated With Malignant Ventricular Arrhythmias
in High-risk Hypertrophic Cardiomyopathy**

Table 1 of the supplementary material

Additional Patient Characteristics

	Total population (N = 78)	Cases (n = 24)	Controls (n = 54)	P
GFR (CKD-EPI), mL/min/1.73m ²	89.3 ± 19.8	90.3 ± 23.0	88.9 ± 18.9	.820
<i>ECG at CT</i>				.107
Sinus rhythm	67 (86)	18 (75)	49 (91)	
Atrial fibrillation	10 (13)	5 (21)	5 (9)	
Pacemaker	1 (1)	1 (4)	0 (0)	
History of any AF	33 (42)	6 (24)	27 (51)	.031
<i>CT platform</i>				.293
Philips	61 (78)	17 (71)	44 (81)	
GE	17 (22)	7 (29)	10 (19)	
CaSc > 0	31 (40)	11 (46)	20 (37)	.464

<i>Number of ICD leads</i>				.021
1 lead: ventricular lead	29 (37)	15 (63)	14 (26)	
2 leads: atrial and ventricular leads	44 (56)	8 (33)	36 (67)	
3 leads: CRT	4 (5)	1 (4)	3 (6)	
2 ventricular leads (1 dysfunctional and discarded)	1 (1)	0 (0)	1 (2)	
<i>Treatment</i>				
Beta-blockers	52 (67)	18 (75)	34 (63)	.368
Calcium blocker	5 (6)	1 (4)	4 (7)	.556
Amiodarone	10 (13)	3 (13)	7 (13)	.912
Dronedarone	1 (1)	0 (0)	1 (2)	.495
Disopyramide	3 (4)	0 (0)	3 (6)	.230
Digoxin	0 (0)	0 (0)	0 (0)	n/a
Acenocumrol / NOAC	17 (22)	5 (21)	12 (22)	.832
Aspirin/other antiplatelet/combo	12 (15)	4 (17)	8 (15)	.882
Statin	22 (28)	5 (21)	17 (31)	.289
Sotalol	4 (5)	2 (8)	2 (4)	.413
Diuretic	9 (12)	4 (17)	5 (9)	.372
ACEI/ARB	9 (12)	2 (8)	7 (13)	.522
Spironolactone/eplerenone	5 (6)	3 (13)	2 (4)	.155
Ranolazine	3 (4)	0 (0)	3 (6)	.230
Ivabradine	1 (1)	1 (4)	0 (0)	.138

ACEI, angiotensin converter enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor antagonist; CaSc, calcium score; CRT, cardiac resynchronization therapy; CT, computed tomography; ECG, electrocardiogram; GE,

General Electric; GFR CKD-EPI, glomerular filtration rate chronic kidney disease epidemiology collaboration; ICD, implantable cardioverter-defibrillator; NOAC, new oral anticoagulant; NYHA, New York Heart Association.

Values are expressed as mean \pm standard deviation or No. (%).

Table 2 of the supplementary material

Implantable Cardioverter-defibrillator Therapies

	Cases (N = 24)	Cases (n = 14)	Cases with ICD for primary prevention (n = 10)	Controls (n = 54)
<i>Type of therapy</i>				
Any appropriate therapy (ATP or ICD) after ICD implantation, n (%)	18 (75)	8 (57)	8 (80)	n/a
ATP	10 (42)	5 (36)	5 (50)	n/a
Shock	12 (50)	6 (43)	6 (60)	n/a
Inappropriate therapy	4 (17)	1 (7)	3 (30)	4 (7)
<i>Time to appropriate ICD therapy</i>				
	Cases (n = 24)	Cases with ICD in secondary prevention (n = 14)	Cases with ICD for primary prevention (n = 10)	Controls (n = 54)
Time from ICD implantation to ATP, d	1141 [503, 1811]	1068 [475, 1319]	1635 [382, 2449]	n/a
Time from ICD implantation to shock, d	468 [244, 1324]	386 [192, 689]	771 [422, 1568]	n/a

ATP, antitachycardia pacing; ICD, implantable cardioverter-defibrillator.

Values are expressed as No. (%) or median [interquartile range].

Table 3 of the supplementary material

Additional CT Data

	Total population (N = 78)	Cases (n = 24)	Controls (n = 54)	P
<i>CT protocol</i>				
Contrast, mL	140.9 ± 23.2	146.7 ± 25.8	138.4 ± 21.7	.146
Absorbed dose, Dose-length Product, mGy•cm	324.1 (274.3-354.1)	324.2 (323.6-377.6)	324.0 (260.3-343.0)	.295
Effective dose, mSv	4.5 (3.8-5.0)	4.5 (4.5-5.3)	4.5 (3.6-4.8)	.295
HR CT, bpm	60.0 (55.0-68.3)	60.0 (54.3-72.5)	60.0 (55.0-68.0)	.922
SBP CT, mmHg	130.0 (115.0-145.0)	133.0 (120.0-149.5)	125.0 (110.0-141.3)	.113
DBP CT, mmHg	80.0 (70.0-85.0)	78.0 (71.0-81.5)	80.0 (70.0-90.0)	.336
<i>Quality and ROI size of septal wall</i>				
SD myocardium precontrast, HU	9.8 (8.6-11.9)	10.6 (9.2-12.7)	9.6 (8.5-11.8)	.138
Myocardial area precontrast, cm ²	4.3 (3.2-5.6)	4.5 (3.4-5.7)	4.3 (3.1-5.7)	.677
SD blood precontrast, HU	10.0 (8.6-12.3)	10.8 (9.5-12.2)	9.8 (8.4-12.3)	.174
Blood area precontrast, cm ²	4.1 (3.1-5.6)	4.4 (3.2-6.0)	4.0 (2.9-5.3)	.502
SD myocardium 25 min, HU	11.1 (9.7-13.8)	11.6 (10.6-14.9)	11.0 (8.8-13.8)	.167
Myocardial area 25 min, cm ²	4.4 (3.5-6.3)	4.6 (3.6-5.8)	4.4 (3.4-6.4)	.961
SD blood 25 min, HU	11.1 (9.6-13.7)	11.5 (10.5-15.5)	10.9 (9.2-13.0)	.123
Blood area blood 25 min, cm ²	4.1 (3.2-5.9)	4.4 (3.3-6.0)	4.0 (3.1-5.8)	.475

CT, computed tomography; DBP, diastolic blood pressure; HR, heart rate; HU, Hounsfield units; ROI, region of interest; SBP, systolic blood pressure; SD, standard deviation.

Table 4 of the supplementary material

Presence of Atrial Fibrillation and Septal Extracellular Volume

	Total	AF	No AF	P
	N = 78	n = 31	n = 47	
Septal ECV %	31.3 ± 7.9	31.3 ± 8.5	31.3 ± 7.1	.976

AF, atrial fibrillation; ECV, extracellular volume; SD, standard deviation.

Values are expressed as mean ± standard deviation.

Table 5 of the supplementary material

Types of Atrial Fibrillation and Septal Extracellular Volume

	Total N = 78	Paroxysmal AF n = 22	Permanent AF n = 9	No AF n = 47	P
Septal ECV %	31.3 ± 7.9	30.8 ± 7.2	32.7 ± 7.1	31.3 ± 8.5	.821

AF, atrial fibrillation; ECV, extracellular volume.

Values are expressed as mean ± standard deviation.